Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals is supported by a differentiated, high-margin royalty aggregation model that combines commercial royalties, milestone income, and Captisol sales with a large and diversified asset base of 15 major commercial-stage royalty streams and more than 200 additional programs. Its outlook improves further as Q2/26 revenue rose 34% year over year to $63.7 million, adjusted core EPS reached $2.37, and management reaffirmed 2026 revenue guidance while lifting the low end of EPS guidance to $9.00–$9.50 on stronger synergies and capital efficiency. The thesis is also reinforced by roughly $1 billion in deployable capital, the XOMA acquisition’s lower OPEX profile, and multiple catalysts including 7 pivotal readouts by the end of 2027 and expanding royalty growth from assets like Filspari, Ohtuvayre, and Ojemda.

Ligand Pharmaceuticals is viewed negatively because its value depends heavily on partnered assets and early-stage programs that remain highly uncertain, including AVC-201’s small Phase 1a dataset of 17 patients, short follow-up, and no disclosed durability. The company’s revenue base is also vulnerable if royalty products face slower sales, Captisol demand is disrupted by manufacturing or IP issues, or commercialization traction remains weak, which could compress future cash flows. In addition, aggressive assumptions around acquisitions and business development may not be realized, while failed trials, poor approvals, or financing constraints could impair share value.